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Abstract 
We aimed to identify new candidate genes potentially involved in early onset 
Alzheimer’s disease (EOAD). Exome sequencing was conducted on 45 EOAD patients 
with either a family history of Alzheimer’s disease (AD, <65 years) or an extremely early 
age at onset (≤55 years) followed by multiple variant filtering according to different 
modes of inheritance. We identified 29 candidate genes potentially involved in EOAD, of 
which the gene TYROBP, previously implicated in AD, was selected for genetic and 
functional follow-up. Using three patient cohorts, we observed rare coding TYROBP 
variants in 9 out of 1110 EOAD patients, whereas no such variants were detected in 1826 
controls (p-value=0.0001), suggesting that at least some rare TYROBP variants might 
contribute to EOAD risk. Overexpression of the p.D50_L51ins14 TYROBP mutant led to 
a profound reduction of TREM2 expression, a well-established risk factor for AD. This is 
the first study supporting a role for genetic variation in TYROBP in EOAD, with in vitro 
support for a functional effect of the p.D50_L51ins14 TYROBP mutation on TREM2 
expression. 
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Alzheimer’s disease; ADRC, Alzheimer’s disease research center; CNR-MAJ, centre national de référence 
pour les malades Alzheimer jeunes; NINCDS-ADRDA , National Institute of Neurological and 
Communicative Disorders and Stroke and the Alzheimer's Disease and Related Disorders Association; 
UTR, untranslated region; GATK, Genome Analysis Toolkit; VQSR, Variant Quality Score Recalibration; 
PCR, polymerase chain reaction; CMC, Combined and Multivariate Collapsing; MAF, minor allele 
frequency; NHD, Nasu-Hakola disease; HDLS, hereditary diffuse leukoencephalopathy with spheroids; 
CSF, cerebrospinal fluid; ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia 
 
1. Introduction 
Alzheimer’s disease (AD) is the most common cause of dementia affecting over 4 million 
individuals in the United States. A minority of patients have early-onset AD (EOAD, 
arbitrarily defined as an age at disease onset before 65 years of age) and a subset of those 
patients carry disease-causing mutations or duplications in one of three genes: APP (MIM 
#104760), PSEN1 (MIM #104311) and PSEN2 (MIM #606889). In the last few years, the 
use of exome sequencing has provided additional insights into the genetics of AD, 
identifying rare variants in SORL1 (MIM #602005), NOTCH3 (MIM #600276), TTC3 
(MIM #602259), PLD3 (MIM #615698) and TREM2 (MIM #605086) as potentially 
involved in the pathophysiology (Cruchaga, et al., 2014, Guerreiro, et al., 2013, 
Guerreiro, et al., 2012, Jonsson, et al., 2013, Kohli, et al., 2016, Pottier, et al., 2012). A 
large proportion of EOAD, however, remains unexplained due to paucity of large 
pedigrees for genetic screening. Although approximately 50% of EOAD patients are 
considered to be sporadic, we hypothesized that either variants compatible with 
autosomal recessive transmission or autosomal dominant transmission with reduced 
penetrance could be responsible for apparently sporadic EOAD patients. In order to 
identify candidate EOAD genes, we exome sequenced 45 EOAD patients from our Mayo 
Clinic EOAD cohort and applied bioinformatics filtering strategies using multiple modes 
of inheritance. Among the identified candidate genes, we chose to follow-up TYROBP 
because of its already reported upregulation in AD brains and its significant role in the 
  
 
 
pathogenesis of late-onset AD (LOAD) (Ma, et al., 2015, Zhang, et al., 2013). Moreover, 
TYROBP is the binding partner of TREM2 (Bouchon, et al., 2001), a well-established 
genetic risk factor for AD (MIM #107741) (Benitez, et al., 2013, Guerreiro, et al., 2013, 
Jin, et al., 2014, Jonsson, et al., 2013, Neumann and Daly, 2013, Pottier, et al., 2013, 
Ruiz, et al., 2014). 
 2. Materials and methods 
2.1. Participants 
Our primary patient series includes 597 EOAD patients which were ascertained from 
1997 to 2015 at Mayo Clinic Jacksonville, Mayo Clinic Rochester, and the Mayo Clinic 
Brain Bank (Table 1). Patients were arbitrarily defined as EOAD if patients presented 
with a clinical diagnosis of AD at or before 65 years of age, or if patients were 
pathologically confirmed with AD at autopsy with an age at death before 70 years 
(irrespective of the onset age). Routine genetic screening of the known genes by Sanger 
sequencing in this EOAD cohort was performed and revealed 35 pathogenic PSEN1 
mutations, 8 APP mutations and duplications, 3 PSEN2 mutations, 5 MAPT mutations, 2 
PGRN mutations and 3 C9ORF72 repeat expansions (Wojtas, et al., 2012). A total of 
1036 white non-Hispanic healthy subjects of similar age and gender ascertained at Mayo 
Clinic Jacksonville were used as a control group (Table 1). 
Additional EOAD patients (n=111), negative for pathogenic mutations in APP, PSEN1 
and PSEN2 genes, were recruited in the Charles F. and Joanne Knight Alzheimer's 
Disease Research Center (ADRC) from Washington University, St Louis, USA 
(Supplementary Table 1). Additionally, 292 healthy individuals ascertained at Charles F. 
and Joanne Knight ADRC were used as control group (Supplementary Table 1). 
Finally, a cohort of French EOAD patients (n=484), negative for pathogenic mutations in 
APP, PSEN1 and PSEN2 genes, were recruited over a 20-year period by the French 
National CNR-MAJ consortium. For comparison, a total of 498 controls were recruited in 
5 different French cities and were all of French ancestry (Supplementary Table 1). 
  
 
 
All patients were diagnosed according to the NINCDS-ADRDA (National Institute of 
Neurological and Communicative Disorders and Stroke and the Alzheimer's Disease and 
Related Disorders Association) criteria (McKhann, et al., 2011). A comprehensive 
clinical examination including personal medical and family history assessment and 
neurological examination was performed on each patient. Patients were considered as 
having a positive family history if at least one first or second degree relative presented 
with a neurodegenerative disorder.  
 
2.2. Standard protocol approvals, registrations, and patient consents 
Written informed consent was obtained from patients and controls individuals for genetic 
analyses at all sites. Each study site obtained approval from the local ethics committee or 
institutional research board. 
 
2.3. Exome sequencing analysis 
Exome sequencing of 23 familial EOAD patients was performed as previously described 
(Guerreiro, et al., 2013). Exomes of the 22 sporadic EOAD patients were captured using 
the Agilent SureSelect Human All Exon V5 plus UTR kit. Sequencing was performed on 
an Illumina Genome HiSeq 2000 by 101-base paired-end reads. Alignment of sequence 
reads was performed against the Human Reference Genome build GRCh37. Variants 
were called using default settings from the GATK tool and following the best practices 
(McKenna, et al., 2010). Low-quality variants that did not pass the Variant Quality Score 
Recalibration (VQSR) filter (DePristo, et al., 2011) were removed. Genetic data from the 
two pilot studies were combined and analyzed using two independent pipelines in order 
  
 
 
to maximize the chance of detecting potentially pathogenic variants. Specifically, filtering 
of variants was performed using the GEM.app application developed at the University of 
Miami (Gonzalez, et al., 2013) and using BioR developed at Mayo Clinic (Kocher, et al., 
2014). All variants identified by at least one analysis pipeline were confirmed by Sanger 
sequencing. 
 
2.4. Mutational analysis 
For sequence validation, specific primers were designed surrounding each rare variant 
detected by Exome sequencing (Supplementary Table 2). In addition, all exonic regions 
of TYROBP were amplified by PCR using specific primers (sequences available upon 
request). Prior to sequencing, PCR products were purified using the AMPure system 
(Beckman Coulter Genomics, Brea, CA, USA). Sequence reactions were purified with 
CleanSEQ (Beckman Coulter Genomics, Brea, CA, USA) and then Sanger sequenced on 
an ABI3730xl Genetic Analyzer. Sequences were analyzed using Sequencher 4.8 
software (Gene Codes Corporation, Ann Arbor, MI, USA). 
 
2.5. Phase determination of p.G2E and p.V55L variants in TYROBP 
Cerebellar RNA was extracted from patient A and a healthy subject using the RNeasy 
Plus Mini Kit (Qiagen, Hilden, Germany) and quality was assessed on an Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), the RNA integrity number 
value obtained were above 8. cDNA was generated from 250ng of RNA from patient A 
and a healthy subject using the SuperScript® III First Strand Synthesis System kit 
(Invitrogen™, Carlsbad, CA, USA). A PCR was performed on the cDNA using a PCR 
  
 
 
primer set with a reverse primer specific for the mutant T allele of the p.V55L variant 
(NM_003332.3:c.163G>T) (primers sequences available upon request) allowing us to 
Sanger sequence the nucleotides surrounding the p.G2E variant.  
 
2.6. Cell culture transfection, mRNA expression and western blotting 
HeLa cells were transiently co-transfected with: 1µg of human TREM2-cMyc and 1μg of 
either TYROBP-eGFP wild-type (TYROBP WT) or TYROBP-D50_L51ins14-eGFP 
mutant (TYROBP D50_L51ins14) plasmids. Control transfections were performed using 
either a co-transfection with human TREM2-cMyc and peGFP plasmids, or using a single 
transfection with 2µg of peGFP plasmid (Supplementary Material).  
For mRNA expression analysis, transfected HeLa cells were harvested and total RNA 
was extracted using the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany). Reverse 
transcription reaction was then performed using the Superscript III system (Life 
Technologies, Carlsbad, CA, USA). Real-time quantitative PCR using an ABI7900 was 
performed in triplicate for each sample using gene expression probes for TYROBP 
(Hs00182426_m1), TREM2 (Hs00219132_m1), eGFP (Mr04097229_mr), and GAPDH 
(Hs02758991_g1). Results were analyzed using SDS software version 2.2 (Life 
Technologies, Carlsbad, CA, USA) and quantifications of TYROBP and TREM2 mRNA 
were first normalized to GAPDH levels and were determined relative to TYROBP WT 
transfected cells (Supplementary Material). 
For western blotting, cells were harvested using radioimmunoprecipitation assay buffer 
(RIPA) (Boston Bioproducts, Ashland, MA). Equal volumes of cell lysate were run on 
10–20% acrylamide tris-glycine gels (Invitrogen, Carlsbad, CA, USA). After transfer, 
  
 
 
total TYROBP levels were detected using an eGFP antibody (MAB3580; Millipore, 
Darmstadt, Germany). TREM2 levels were assessed using a cMyc antibody (9E10; 
Roche, Penzberg, Germany). A GAPDH antibody was used as a protein loading control 
to visualize protein loading (Meridian Life Science, Memphis, ME, USA). Quantitative 
values from each blot were obtained using ImageJ 1.44 (National Institutes of Health, 
Bathesda, MD, USA). Numerical values of optical intensity were obtained by measuring 
the average pixel intensity per area for each band. Band intensity was then normalized to 
the total amount of protein using GAPDH. Protein expression level was assessed relative 
to the TYROBP WT condition (Supplementary Material).  
 
2.7. Statistical analyses 
Statistical analyses were performed using the Combined and Multivariate Collapsing test 
(CMC) using 100,000 permutation and the R software version 3.1.2 (2014-10-3, Vienna, 
Austria) (Li and Leal, 2008). Rare variants (minor allele frequency < 1%) affecting the 
TYROBP protein sequence were considered. CMC test collapses all rare variants and 
compares the proportions of variant carriers among cases and controls. No adjustment for 
age and gender were performed. 
Statistical analyses for the western blot quantifications and the mRNA experiments were 
performed using a one-way ANOVA followed by Student t-tests for TREM2 and 
TYROBP levels using GraphPad Prism software (version 6.07 for Windows, GraphPad 
Software, La Jolla, CA, USA).  
  
 
 
3. Results 
3.1. Identification of potential candidate genes by exome sequencing 
We performed two independent exome sequencing pilot studies on 45 white non-
Hispanic EOAD patients selected from the overall Mayo Clinic cohort negative for 
mutations in the known genes: 23 patients with at least one affected relative with AD 
(mean age at onset: 56.7 years), and 22 patients with extreme young onset of EOAD (age 
at onset at or before 55, mean age at onset: 52.0 years) with no reported family history. 
Three different bioinformatic filtering strategies were subsequently employed to select 
candidate EOAD genes from our pilot sequencing dataset of 45 exomes (Table 2). First, 
we assessed our entire patient cohort (n=45) and selected heterozygous rare coding 
variants with a minor allele frequency (MAF) <0.1% in the NHLBI GO Exome 
Sequencing Project (ESP), Seattle, WA (URL: http://evs.gs.washington.edu/EVS/) based 
on the European cohort. Only variants affecting the protein sequence and shared between 
at least two individuals were selected (autosomal dominant model). Additionally, variants 
could not be present in more than 2 families in the GEM.app database. Using this strategy 
we were able to detect and validate 15 variants in 15 candidate genes (Table 2; 
Supplementary Table 2). Second, we focused on sporadic EOAD patients (n=22) and a 
potential recessive mode of inheritance. We selected all homozygous variants with a less 
stringent MAF of less than 5% in ESP European cohort that affected protein sequence, 
which resulted in the identification of 13 variants in 13 candidate genes (Table 2; 
Supplementary Table 2, homozygous model). Finally, in the same cohort of sporadic 
EOAD patients (n=22), we searched for compound heterozygous variants with a 
MAF<5% in the ESP European cohort that affected the protein sequences and were 
  
 
 
present in at least two individuals. The variants identified were filtered out if present at 
the homozygous state in ExAC European population. This strategy revealed 4 validated 
variants in 2 candidate genes (Table 2, Supplementary Table 2, compound heterozygous 
model). Of note, variants were considered as compound heterozygous when at least two 
variants were found in the same gene. 
 
3.2. Evaluation of TYROBP rare variants in the etiology of EOAD 
Interestingly, the gene encoding TYROBP (MIM #604142) was identified using both the 
autosomal dominant and the compound heterozygote disease strategy, due to presence of 
variants c.5G>A (p.G2E) and c.163G>T (p.V55L) in two unrelated sporadic EOAD 
patients (patient A and patient B). Cerebellar brain tissue, available for patient A, allowed 
the extraction of mRNA and subsequent cDNA analysis, which demonstrated that both 
variants were inherited in cis, arguing in favor of a possible autosomal dominant mode of 
action for TYROBP variants in EOAD (Fig. 1A; Supplementary Material).  
Given the strong functional link between TYROBP and AD, we expanded our genetic 
analysis of rare coding TYROBP variants in EOAD. We sequenced TYROBP in the entire 
EOAD Mayo Clinic cohort (n=597 including 43 other than white non-Hispanic patients 
and 56 mutation carriers) as well as in 1036 white non-Hispanic healthy subjects of 
similar age and gender ascertained at Mayo Clinic Jacksonville. This led to the 
identification of 4 additional rare variants (MAF<1%) affecting the coding region in 7 
additional EOAD patients: c.67C>T (p.R23C), c.266C>T (p.S89L), c.151_152ins42 
(p.Asp50_Leu51ins14), and c.238C>T (p.R80W) (Fig. 1B, Table 2, Table 3; 
Supplementary Table 3). No rare coding variants that affected the protein sequence were 
  
 
 
found in healthy subjects. Notably, of the 9 EOAD patients carrying rare TYROBP 
variants, 3 patients also carried known AD gene mutations: the p.R80W variant was 
found twice in two Hispanic patients also harboring the pathogenic PSEN1 c.617G>C 
(p.G206A) mutation; and the p.S89L variant was found in an APP duplication carrier. 
These patients were excluded from further statistical analysis. By collapsing rare coding 
variants with a MAF<1% and comparing the overall frequency of such variants between 
all white non-Hispanic EOAD patients without mutations in the known genes (n=6, 
representing 1.17% of 509 EOAD patients) and healthy subjects (n=1036; no mutation 
detected), we identified a significant enrichment in EOAD patients (p-value=0.002; CMC 
test). 
To further substantiate this finding we examined two additional independent cohorts for 
the presence of rare coding variants in TYROBP. We studied 111 EOAD patients without 
mutations in the known AD genes and 292 healthy individuals from the Knight ADRC at 
Washington University by Sanger sequencing and we assessed exome sequencing data 
available on 484 French EOAD patients and 498 French controls without mutation in the 
known AD genes. Interestingly, we identified and confirmed by Sanger sequencing two 
rare coding variants in three unrelated French patients (Nicolas, et al., 2015), whereas no 
rare coding variants were detected in controls (n=595 EOAD patients and n=790 healthy 
subjects, Table 3, Supplementary Table 3). When combining these results, we observed a 
significant association between rare coding variants and EOAD: 6 rare coding TYROBP 
variants were identified in 9 unrelated patients out of 1110 white non-Hispanic EOAD 
patients as compared to an absence of such variants in 1826 healthy subjects (p-
value=0.0001; CMC test). Of note, none of the patients harboring rare TYROBP variants 
  
 
 
was homozygous for the APOE ε4 allele and the presence of the ε4 haplotype does not 
appear to have an effect on age at onset (Table 3, Supplementary Table 3).  
 
3.3. In vitro functional analysis of TYROBP p.D50_L51ins14 
To provide support for a functional effect of at least one of the identified TYROBP 
variants, we selected variant TYROBP p.D50_L51ins14 that overlaps with a critical 
amino-acid for the binding of TYROBP to TREM2 (D50). It was shown that an artificial 
mutation of amino-acid D50 reduced the ability of TYROBP to bind TREM2 and 
stabilize TREM2 C-terminal fragments resulting from γ-secretase cleavage (Wunderlich, 
et al., 2013,Zhong, et al., 2015). We identified the p.D50_L51ins14 mutation in a 
probable AD patient with an age at disease onset of 62 years. This patient showed a clear 
family history with a diagnosis of AD in the patient’s father.  
We co-expressed TYROBP p.D50_L51ins14 along with wild-type human TREM2 in 
HeLa cells in order to evaluate the impact of TYROBP p.D50_L51ins14 mutation on 
TYROBP and TREM2 levels. We found that the mutant form of TYROBP was expressed 
at a significantly lower protein level as compared to TYROBP WT (mean =0.30, 
SE=0.12; p-value=0.001, Student t-test; Fig. 2A and B), despite equal wild-type and 
mutant TYROBP mRNA expression (mean=0.93, SE=0.03; p-value=0.19, Student t-test; 
Fig. 2C). Moreover, TREM2 protein levels were significantly reduced in cells transfected 
with p.D50_L51ins14 mutant TYROBP as compared to cells transfected  with wild-type 
TYROBP (mean=0.22, SE=0.02; p-value <0.0001, Student t-test; Fig. 2A and B). 
Interestingly, the reduction in TREM2 expression is also present at the mRNA level but 
to a far lesser extent than the protein level (mean=0.73, SE=0.02; p-value <0.0001, 
  
 
 
Student t-test; Fig. 2C). Our control experiment in which we co-transfected TREM2 with 
eGFP (in the absence of TYROBP overexpression) also showed significantly reduced 
levels of TREM2 mRNA (mean=0.66, SE=0.02; p-value <0.0001, Student t-test; Fig. 2C) 
and TREM2 protein (mean=0.18, SE=0.05; p-value <0.0001, Student t-test; Fig. 2A and 
B) similar to the decrease observed when co-expressed with the TYROBP mutant.
  
 
 
4. Discussion 
In this study, we used an original bioinformatics filtering strategy to evaluate the impact 
of rare autosomal dominant and recessive variants in the genetics of EOAD and nominate 
potential candidate EOAD genes. We present a list of 29 candidate genes that could be 
considered in future genetics studies. We selected one gene from our list, TYROBP, based 
on its functional link to AD, and further characterized its potential involvement in 
EOAD. We first detected a nominally significant enrichment of rare coding TYROBP 
variants in EOAD compared to controls. Second, we identified one rare TYROBP variant 
with a profound effect on TREM2 expression in cell culture.  
TYROBP was nominated as a candidate EOAD gene as part of our autosomal dominant 
and autosomal recessive (compound heterozygote) filtering strategies; however, brain 
mRNA and cDNA expression studies suggest that the observed variants were in cis, 
thereby favoring the hypothesis of an autosomal dominant inheritance pattern for 
TYROBP variants, possibly with reduced penetrance. TYROBP encodes a type I 
transmembrane protein consisting of a signal peptide sequence, a transmembrane 
segment and a cytoplasmic region containing an immunoreceptor tyrosine-based 
activation motif (ITAM; Fig. 1B). Within the central nervous system, TYROBP is 
preferentially expressed in microglia (Hickman, et al., 2013). Binding to its ligands, such 
as TREM2, leads to phosphorylation of TYROBP’s tyrosine residues (positions 91 and 
102) and recruitment of downstream proteins, which regulates pro-inflammatory 
responses and phagocytosis (Malik, et al., 2015, Paradowska-Gorycka and Jurkowska, 
2013, Zhong, et al., 2015). In addition to its major role in immune system regulation and 
phagocytosis, TYROBP might be involved in Aβ turnover (Zhang, et al., 2013). Similar 
  
 
 
to TREM2 mutations, loss-of-function mutations in TYROBP have already been described 
in the recessively inherited Nasu-Hakola disease (NHD, MIM #221770) (Paloneva, et al., 
2000), a rare condition characterized by systemic bone cysts and dementia. Moreover, 
TYROBP regulates macrophage proliferation through CSF1R (MIM #164770), which is 
encoded by a gene previously implicated in hereditary diffuse leukoencephalopathy with 
spheroids (HDLS, MIM #221820), a white-matter disease clinically characterized by 
behavioral, cognitive and motor abnormalities (Rademakers, et al., 2012). The 
mechanism leading to cognitive decline in these diseases is still under investigation; 
however, partial loss of the CSF1R/TYROBP signaling pathway has been suggested to be 
responsible for the neurological phenotypes observed in NHD and HDLS.  
In our study, we detected an enrichment of TYROBP rare coding variants in EOAD 
compared to controls. We acknowledge that the level of significance did not reach the 
threshold of exome-wide significance (2.5x10-6 for Bonferroni correction accounting for 
~20,000 genes); however, we argue that our results are at least suggestive of a subset of 
TYROBP variants impacting EOAD disease risk. Remarkably, in line with this 
hypothesis, overexpression of TYROBP p.D50_L51ins14 leads to a loss of TYROBP 
protein and an almost total loss of TREM2 protein expression in cell culture. This 
reduction in TREM2 protein levels was partially explained by a 30% loss in TREM2 
mRNA expression but other mechanisms such as destabilization of TREM2 protein may 
also be involved. In either way, the strong reduction in TREM2 levels when co-expressed 
with mutant TYROBP suggests that, based on the current cellular model, the 
p.D50_L51ins14 mutation leads to a loss of TYROBP expression and/or function and 
reduced TREM2 levels. In this respect it is important to note that a decrease in soluble 
  
 
 
TREM2 expression has been reported in cerebrospinal fluid (CSF) of patients harboring 
heterozygous variants in TREM2, which are known to lead to NHD in the homozygous 
state (Piccio, et al., 2016). Additionally, other rare variants in TREM2 that have been 
reported as risk factors for AD correlate with a lower abundance of TREM2 in the CSF. 
Our results for the p.D50_L51ins14 mutation align with those findings and reinforce the 
idea that a loss of TREM2/TYROBP function might contribute to the physiopathology of 
AD. Whether and how the other 5 observed TYROBP rare variants affect TYROBP 
biology remains to be studied. Two of the TYROBP variants (p.G2E and p.R23C) are 
located in the signal peptide segment of TYROBP and might affect TYROBP localization 
or processing. Moreover, variant p.V47A is located in close proximity to 
p.D50_L51ins14 and might similarly affect the TREM2-TYROBP interaction and 
TREM2 stabilization. Finally, we note that we also detected rare coding TYROBP 
variants in 3 EOAD patients already harboring pathogenic mutations in APP and PSEN1. 
It remains possible that these TYROBP variants contribute to the disease in these patients, 
especially in light of the oligogenic disease mechanism that is gaining attention in other 
neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and 
frontotemporal dementia (FTD) (van Blitterswijk, et al., 2012). 
In addition to TYROBP, we provide a list of 28 additional potential EOAD genes. Two 
notable candidates, which we have not yet followed-up genetically, are AMPH (MIM 
#600418) and CD300E (MIM #609801). Specifically, we identified in two unrelated 
individuals a non-sense variant in AMPH which encodes the amphiphysin-1 protein 
involved in synaptic endocytosis (Wu, et al., 2009). AMPH1 has been shown to be 
reduced in frontal and temporal cortex of AD patients as well as in the JNPL3 tauopathy 
  
 
 
mouse model (De Jesus-Cortes, et al., 2012), suggestive of a role in tau-mediated 
neurodegeneration. Interestingly, amphiphysin-2, also known as BIN1 (MIM #601248), 
resides at one of the most significant genome-wide association loci for LOAD risk 
(Lambert, et al., 2013). We also detected a non-sense variant in CD300E, which was 
present in two unrelated individuals. CD300E is a type I transmembrane protein and was 
shown to interact with TYROBP (Brckalo, et al., 2010). Whether AMPH, CD300E or any 
of the other candidate genes identified in our study are implicated in EOAD will require 
systematic mutation and association analyses in large EOAD and control cohorts. 
Similarly, in the near future, large scale on-going sequencing projects focused on LOAD 
may allow evaluating the impact on LOAD risk of the candidate genes identified in the 
current study. 
 
5. Conclusions 
In summary, we propose the use of extreme phenotypes such as very young EOAD 
patients or EOAD patients with a family history, as well as the use of multiple 
prioritization strategies as an efficient strategy to identify candidate genes for 
neurodegenerative disorders. We further present, for the first time, an association of rare 
coding variants in TYROBP with EOAD, which adds to the growing body of evidence 
suggesting that TYROBP is an important player in the physiopathology of AD. 
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TABLES 
Table 1. Mayo Clinic EOAD and control cohort characteristics 
 
  
 
Mean age 
at onset 
in years 
 
(range) 
Mean age 
at death 
in years 
 
(range) 
Mean age 
last visit  
in years 
 
(range) 
% 
females  
 
 
(n) 
% 
White 
non-
Hispanic  
(n) 
% 
Hispanic   
 
 
(n) 
%  
Black or 
African 
American  
(n) 
% 
Asian 
 
 
(n) 
% 
Mutation 
carriers 
 
(n) 
EOAD 
patients 
(n=597) 
55.93  
(25–67) 
63.95  
(36-79) 
NA 49.4  
(295) 
92.8  
(554) 
2.7  
(16) 
4.0  
(24) 
0.5  
(3) 
8.7  
(52) 
Controls 
(n=1036) 
NA NA 75  
(27-99) 
53.0  
(549) 
100.0 
(1036) 
NA NA NA NA 
Key: EOAD, Early Onset Alzheimer’s Disease; n, number; NA, Not Applicable 
  
 
 
Table 2. Strategies used to identify candidate EOAD genes in exome sequencing data 
Strategy Autosomal Dominant Autosomal Recessive 
Coding changes 
Missense/Stop-gain/Stop-
loss/Splice/Indels/Start 
loss and gain 
Missense/Stop-gain/Stop-
loss/Splice/Indels/Start 
loss and gain 
Missense/Stop-gain/Stop-
loss/Splice/Indels/Start 
loss and gain 
Number of EOAD 
patients 
n=45 n=22 n=22 
Variant types Heterozygous variants Homozygous variants 
Compound heterozygous 
variants 
ESP European American 
MAF* 
<0.1% <5% <5% 
HapMap European 
MAF* 
<0.1% <5% <5% 
Additional filters 
Same variant in two 
unrelated individuals 
 
No additional filter 
Same variant in at least 
two unrelated individuals 
No more than 2 families in 
the GEM.app** database 
with the same variant 
No homozygotes in ExAC 
European*** 
Number of candidate 
genes 
15 13 2 
Key: EOAD, Early Onset Alzheimer’s Disease; n, number of patients included 
*Minor allele frequency (MAF) from the Exome Variant Server, NHLBI GO Exome Sequencing Project (ESP), 
Seattle, WA (URL: http://evs.gs.washington.edu/EVS/)  
**Filtering was done on allele count from the GEnomes Management Application (GEM.app) database, regrouping 
exome sequencing from 2200 families (September 2014). 
***Filtering was done on Broad Institute Exome Aggregation Consortium (ExAC) genotypes. 
  
 
 
 
 
Table 3. Non-Hispanic whites without mutations in known AD genes included in the 
statistical analyses 
Site Patients Healthy individuals 
 
TYROBP mutation 
carriers 
Non mutation 
carriers 
TYROBP mutation 
carriers 
Non mutation 
carriers 
Mayo Clinic* 6 509 0 1036 
Knight ADRC 0 111 0 292 
France 3 481 0 498 
Total** 9 1101 0 1826 
*: pvalue=0.002 
**: pvalue=0.0001 
 
FIGURES LEGENDS 
Fig. 1. Molecular genetic analysis of TYROBP. 
(A) Panel A includes a chromatogram of several bases surrounding the p.G2E variant 
(red square) of patient A and an healthy subject. (B) Schematic representation of 
TYROBP protein along with its different domains and the rare coding variants identified 
in the overall EOAD cohort. A PCR was performed on the cDNA from patient A using a 
PCR primer set with a reverse primer specific for the mutant T allele of the p.V55L 
variant (NM_003332.3:c.163G>T) allowing us to specifically amplify the chromosome 
carrying the c.163T allele. This PCR fragment also spanned the sequence surrounding the 
p.G2E (NM_003332.3:c.5G>A) variant. Sanger sequencing of the PCR product showed 
the mutant A allele of the p.G2E variant suggesting that the variant is in cis with the 
p.V55L variant. 
Fig. 2. Effect of TYROBP mutant p.D50_L51ins14 on TREM2 expression. 
  
 
 
(A) Co-expression of TYROBP mutant with TREM2 decreases the level of TREM2 
protein expression. Western blot of HeLa cells transfected with TREM2-Myc in 
combination with wild-type TYROBP-eGFP (TYROBP WT-eGFP) or with the 
p.D50_L51ins14 (TYROBP mutant-eGFP) or a vector control eGFP. The levels of 
TYROBP and TREM2 were visualized using an eGFP or cMyc antibody, respectively. 
GAPDH was used as loading control. (B) Quantification of TYROBP and TREM2 
protein levels in HeLa cells transfected as described in (A). Quantification is assessed 
relative to the TYROBP WT-eGFP transfection condition after normalization to GAPDH 
levels. (C) Quantification of mRNA levels in HeLa cells transfected as described in (A). 
**: p<0.01; ***: p<0.0001, Student t-test on n≥4 replicates. 
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Highlights. 
 Exome sequencing of highly selected EOAD patients nominates 29 candidate genes 
 Rare coding variants in TYROBP are genetically associated with EOAD 
 TYROBP p.D50_L51ins14 is a potentially pathogenic variant altering TREM2 levels 
*Highlights (for review)
